These innovative compounds represent a significant progression in the therapy of type 2 diabetes. Retatrutide, a triple GLP-1 and GIP receptor agonist, demonstrates remarkable efficacy in lowering blood glucose levels. https://robertrffl582345.ja-blog.com/39357829/novel-glp-1-receptor-agonists-retatrutide-and-trizepatide